新型氯贝丁酯类似物（BM 15.075）在降血脂治疗中口服抗凝剂与血小板功能（作者译）
[Oral anticoagulants and platelet function in hypolipemic therapy using a new clofibrate analog (BM 15.075) (author's transl)].
作者信息
Zimmermann R, Hoffrichter A, Walter E, Ehlers W, Andrassy K, Lang P D, Schlierf G, Weber E, Barth P
出版信息
Dtsch Med Wochenschr. 1977 Apr 8;102(14):509-12. doi: 10.1055/s-0028-1104921.
When testing the effect of a new clofibrate analogue (BM 15.075) on oral anticoagulation and blood clotting in 15 patients for over four weeks it was demonstrated that, depending on the dose of the drug, there was an increase in anticoagulation. The dose of phenprocoumon had to be reduced by 20.6 or 28.7%, respectively, when BM 15.075 was given at a dose of 450 or 600 mg. There was an inhibition of collagen-induced platelet-aggregation. In parallel there was an increase in bleeding time. Fibrinogen concentration was slightly but statistically not significantly decreased. Euglobulin lysis was shortened, especially if previously abnormally long. There was no direct influence on other plasmatic clotting factors.
在15名患者中测试一种新的氯贝丁酯类似物（BM 15.075）对口服抗凝和血液凝固的影响超过四周，结果表明，根据药物剂量不同，抗凝作用增强。当给予450或600毫克剂量的BM 15.075时，苯丙香豆素的剂量必须分别减少20.6%或28.7%。存在对胶原诱导的血小板聚集的抑制作用。同时出血时间延长。纤维蛋白原浓度略有下降，但在统计学上无显著意义。优球蛋白溶解时间缩短，尤其是之前异常延长的情况。对其他血浆凝血因子无直接影响。
Zotero 插件